FCH-PET/CT identifies bone metastases in prostate cancer patients

10/8/2009 | HealthImaging.com

An Austrian study on 70 men with biopsy-proven prostate cancer found that PET/CT using F18 fluorocholine had 79% sensitivity, 97% specificity and 84% accuracy in identifying the patients with bone metastases. Of the 262 lesions that showed increased uptake in the study, 210 were determined to be bone metastases. The findings point to the potential of FCH-PET/CT in early diagnosing of bone metastases in prostate cancer patients.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI